Peripheral blood TCR marker of diffuse large B-cell lymphoma as well as detection kit and application of peripheral blood TCR marker

A marker, lymphoma technology, applied in the field of genetic engineering, can solve the problems of judging disease, patient physical injury, increasing patient burden, etc., achieving high specificity and accuracy, reducing detection costs, and low labor costs.

Pending Publication Date: 2021-07-09
CHENGDU EXAB BIOTECH CO LTD
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] To sum up, blood tests in non-invasive examinations can only roughly determine the existence of diseases, and cannot distinguish specific diseases; bone marrow aspiration and biopsy in invasive examinations require biopsy, sampling is difficult, and cannot be used as a means of real-time monitoring. damage to the patient's body
It is often necessary to combine the results of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peripheral blood TCR marker of diffuse large B-cell lymphoma as well as detection kit and application of peripheral blood TCR marker
  • Peripheral blood TCR marker of diffuse large B-cell lymphoma as well as detection kit and application of peripheral blood TCR marker
  • Peripheral blood TCR marker of diffuse large B-cell lymphoma as well as detection kit and application of peripheral blood TCR marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1 Obtaining Diffuse Large B-cell Lymphoma TCR Marker CDR3 Sequence Set Through Immunogram Analysis

[0045] 1. Sampling and immune map analysis (for the method, refer to the patent with application number 201910300069.9)

[0046] Collect 1301 control groups (including healthy people and patients with non-tumor diseases, 1300 people for model building, 1 healthy person for verification), 41 diffuse large B-cell lymphoma patients (40 people for model building, 1 person For verification) and peripheral blood (10mL per person) of a subject with unknown health status, the antigenic determinant 3 (CDR3) amino acid sequence of the TCR of the subject and the control group was obtained by high-throughput sequencing, ensuring that each The total number of CDR3 sequences of functional TCR in the sample should not be less than 25,000;

[0047] 2. Perform random non-replacement sampling on the sequences of samples whose total number of CDR3 sequences of each functional TCR ...

Embodiment 2

[0053] Example 2 Verification of the specificity of the diffuse large B-cell lymphoma TCR marker CDR3 sequence set

[0054] 1. Sampling and immune map analysis (for the method, refer to the patent with application number 201910300069.9)

[0055] The peripheral blood (10 mL per person) of 577 tumor patients with non-diffuse large B-cell lymphoma and 7 subjects with unknown health status was collected, and the epitope 3 of TCR of the subjects and the control group was obtained by high-throughput sequencing (CDR3) amino acid sequence, to ensure that the total number of functional TCR CDR3 sequences of each sample is not less than 25,000; random non-replacement sampling is performed on the sequences of samples whose total number of functional TCR CDR3 sequences is higher than 30,000, so that The total number of CDR3 sequences in this sample is 30,000. So far, the total number of functional TCR CDR3 sequences contained in all samples is 25,000-30,000.

[0056] 2. Randomly select ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a peripheral blood TCR marker of diffuse large B-cell lymphoma as well as a detection kit and application of the peripheral blood TCR marker. The marker comprises at least one of proteins of which the sequences are as shown in SEQ ID NO.1-100. On the basis of a high-throughput sequencing method, only a small amount of peripheral blood needs to be adopted, RNA is extracted, an immune map library is established by treating a sample, then through high-throughput sequencing and TCR data analysis, firstly, a characteristic TCR sequence in the peripheral blood of the diffuse large B-cell lymphoma is determined, and then a test result of a sample to be tested is compared with the characteristic TCR sequence, and therefore, whether the patient suffers from the diffuse large B-cell lymphoma or not is determined. According to the invention, a huge number of diffuse large B-cell lymphoma specific TCR sequences can be compared at the same time, and compared with single detection of one or more markers, the kit has higher specificity and accuracy, and the diagnosis efficiency is improved.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering, and in particular relates to a diffuse large B-cell lymphoma peripheral blood TCR marker, a detection kit and application thereof. Background technique [0002] Non-Hodgkin Lymphoma (NHL) is a general term for a group of malignant tumors originating from lymph nodes and lymphoid tissues. NHL lesions mainly occur in lymph nodes, spleen, thymus and other lymph organs, and can also occur outside lymph nodes. Malignant neoplasms of lymphoid tissues and organs of the lymphohematopoietic system. According to the source of cells, it can be divided into three basic types: B cell, T cell and NK / T cell NHL. [0003] Epidemiology shows that there are relatively few patients with non-Hodgkin's lymphoma in my country, but the incidence has gradually increased in recent years. A recent survey shows that non-Hodgkin's lymphoma accounts for 4% of new tumors each year and 90% of all malignant lympho...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/574G01N33/68A61K38/17A61P35/00C07K14/725
CPCG01N33/57407G01N33/57488G01N33/6854A61K38/1774A61P35/00C07K14/7051G01N2333/7051
Inventor 张志新卓越杨鑫
Owner CHENGDU EXAB BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap